

Christian F Singer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7800402/publications.pdf>

Version: 2024-02-01

174
papers

9,022
citations

81743

39
h-index

48187

88
g-index

181
all docs

181
docs citations

181
times ranked

12711
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	3.8	1,898
2	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	1.1	513
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
4	Adjuvant denosumab in breast cancer (ABCSC-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2015, 386, 433-443.	6.3	444
5	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
7	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
8	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
9	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
10	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
11	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSC-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 339-351.	5.1	167
12	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	160
13	RANKL/RANK control <i>Brca1</i> mutation-driven mammary tumors. <i>Cell Research</i> , 2016, 26, 761-774.	5.7	128
14	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
15	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	3.4	121
16	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
17	Combined genetic and splicing analysis of <i>BRCA1</i> c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	1.4	106
18	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93

#	ARTICLE	IF	CITATIONS
19	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
20	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	0.8	90
21	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
22	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
23	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
24	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
25	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 395-405.	13.9	82
26	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1888.	3.8	79
27	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
28	Guidance Statement On <i>BRCA1/2</i> Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
29	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
30	Quantitative Sodium MR Imaging at 7 T: Initial Results and Comparison with Diffusion-weighted Imaging in Patients with Breast Tumors. <i>Radiology</i> , 2016, 280, 39-48.	3.6	69
31	Age-specific ovarian cancer risks among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	0.6	65
32	Differential gene expression profile in breast cancer-derived stromal fibroblasts. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 273-281.	1.1	64
33	Hormone replacement therapy after menopause and risk of breast cancer in <i>BRCA1</i> mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	1.1	55
34	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
35	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2 ⁺ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	3.2	54
36	Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect". <i>BMC Cancer</i> , 2016, 16, 436.	1.1	49

#	ARTICLE	IF	CITATIONS
37	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
38	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
39	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 11600-11613.	0.8	43
40	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
41	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	2.2	41
42	Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0125317.	1.1	40
43	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
44	Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018, 9, 812-823.	0.8	35
45	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
46	Oral contraceptive use and ovarian cancer risk for <i>BRCA1/2</i> mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	0.7	34
47	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a <i>BRCA1</i> and <i>BRCA2</i> Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	1.4	33
48	Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1667-1671.	1.2	33
49	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
50	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
51	Influence of Orally Administered Probiotic <i>Lactobacillus</i> Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo-Controlled Double-Blinded Pilot Study. <i>Breast Care</i> , 2017, 12, 335-339.	0.8	30
52	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
53	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	3.2	29
54	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020, 134, 99-106.	1.3	29

#	ARTICLE	IF	CITATIONS
55	Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. <i>Breast Care</i> , 2017, 12, 401-408.	0.8	28
56	Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). <i>Breast</i> , 2021, 60, 98-110.	0.9	28
57	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2016, 7, 86687-86694.	0.8	28
58	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 11-16.	1.1	27
59	Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer. <i>Translational Oncology</i> , 2013, 6, 715-IN27.	1.7	26
60	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
61	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	1.1	26
62	The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. <i>Breast</i> , 2017, 33, 153-158.	0.9	25
63	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer: an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60.	1.3	25
64	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	1.1	24
65	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	1.3	24
66	7T CEST MRI: A potential imaging tool for the assessment of tumor grade and cell proliferation in breast cancer. <i>Magnetic Resonance Imaging</i> , 2019, 59, 77-87.	1.0	23
67	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 500-500.	0.8	23
68	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
69	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
70	Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. <i>Carcinogenesis</i> , 2014, 35, 2447-2451.	1.3	21
71	HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. <i>PLoS ONE</i> , 2016, 11, e0146311.	1.1	21
72	Cadherin-11 expression is upregulated in invasive human breast cancer. <i>Oncology Letters</i> , 2016, 12, 4393-4398.	0.8	21

#	ARTICLE	IF	CITATIONS
73	The association between smoking and cancer incidence in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2018, 142, 2263-2272.	2.3	20
74	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
75	Nonsurgical Prevention Strategies in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Breast Care</i> , 2021, 16, 144-148.	0.8	19
76	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
77	Association of breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
78	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
79	Association between family history, mutation locations, and prevalence of <i>BRCA1</i> or <i>BRCA2</i> mutations in ovarian cancer patients. <i>Cancer Medicine</i> , 2019, 8, 1875-1881.	1.3	17
80	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 334-345.	3.2	17
81	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	3.2	17
82	Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. <i>Cancer Letters</i> , 2019, 459, 1-12.	3.2	16
83	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
84	Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 507-507.	0.8	15
85	Central European <i>BRCA2</i> mutation carriers: Birth cohort status correlates with onset of breast cancer. <i>Maturitas</i> , 2014, 77, 68-72.	1.0	14
86	The pre-analytical processing of blood samples for detecting biomarkers on protein microarrays. <i>Journal of Immunological Methods</i> , 2015, 418, 39-51.	0.6	14
87	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	1.1	12
88	Oophorectomy and risk of contralateral breast cancer among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	1.1	12
89	PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer. <i>PLoS ONE</i> , 2017, 12, e0172911.	1.1	12
90	Prospective evaluation of body size and breast cancer risk among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	0.9	11

#	ARTICLE	IF	CITATIONS
91	Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool. <i>PLoS ONE</i> , 2018, 13, e0200559.	1.1	11
92	Patient satisfaction after breast cancer surgery. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 6-13.	1.0	11
93	Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 593.	1.1	11
94	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
95	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	1.1	10
96	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	0.6	10
97	Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer. <i>Journal of Proteome Research</i> , 2016, 15, 1534-1545.	1.8	9
98	Radiotherapy-Induced Fatigue in Breast Cancer Patients. <i>Breast Care</i> , 2021, 16, 236-242.	0.8	9
99	ESR1 -Amplification-Associated Estrogen Receptor β Activity in Breast Cancer. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 751-752.	3.1	8
100	AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 123-127.	0.8	8
101	Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. <i>PLoS ONE</i> , 2017, 12, e0189641.	1.1	8
102	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. <i>Cancer Investigation</i> , 2018, 36, 378-388.	0.6	8
103	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Openâ€”Cancer Horizons pro and con discussion. <i>ESMO Open</i> , 2019, 4, e000565.	2.0	8
104	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2022, 164, 514-521.	0.6	8
105	Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. <i>PLoS ONE</i> , 2017, 12, e0185566.	1.1	7
106	Co-expressed genes enhance precision of receptor status identification in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 313-326.	1.1	7
107	Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study. <i>Radiology</i> , 2021, 299, 63-72.	3.6	7
108	Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer. <i>Neoplasma</i> , 2021, 68, 342-351.	0.7	7

#	ARTICLE	IF	CITATIONS
109	Response Prediction to Neoadjuvant Chemotherapy: Comparison between Pre-Therapeutic Gene Expression Profiles and In Vitro Chemosensitivity Assay. PLoS ONE, 2013, 8, e66573.	1.1	7
110	Gene expression information improves reliability of receptor status in breast cancer patients. Oncotarget, 2017, 8, 77341-77359.	0.8	7
111	IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways. Oncotarget, 2019, 10, 3491-3505.	0.8	7
112	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	1.1	6
113	Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. Journal of Clinical Oncology, 2015, 33, 504-504.	0.8	6
114	Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. Wiener Medizinische Wochenschrift, 2015, 165, 387-394.	0.5	5
115	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	2.3	5
116	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 545-555.	1.4	5
117	Breast cancer risk after age 60 among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	1.1	5
118	Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	5
119	Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. Endocrine-Related Cancer, 2009, 16, 73-83.	1.6	4
120	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. Clinical Breast Cancer, 2015, 15, 505-511.	1.1	4
121	Therapeutic Strategies in Triple-Negative Breast Cancer. Breast Care, 2017, 12, 6-7.	0.8	4
122	Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer. Breast Journal, 2017, 23, 352-353.	0.4	4
123	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. BMC Cancer, 2019, 19, 695.	1.1	4
124	Complication rates among women undergoing preventive mastectomy: An Austrian registry. Breast Journal, 2020, 26, 1639-1644.	0.4	4
125	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-“positive Early Breast Cancer: Results from the ABCSG Trial 5. Clinical Cancer Research, 2020, 26, 5682-5688.	3.2	4
126	Invasive lobular carcinoma: clinicopathological features and subtypes. Journal of International Medical Research, 2021, 49, 030006052110170.	0.4	4

#	ARTICLE	IF	CITATIONS
127	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 577-577.	0.8	4
128	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptorâ€‘positive (HR+), human epidermal growth factor receptor 2â€‘negative (HER2â€‘) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1006-1006.	0.8	4
129	Microarray Normalization Revisited for Reproducible Breast Cancer Biomarkers. <i>BioMed Research International</i> , 2020, 2020, 1-27.	0.9	3
130	Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype. <i>Breast Care</i> , 2020, 15, 648-654.	0.8	3
131	Decision theory for precision therapy of breast cancer. <i>Scientific Reports</i> , 2021, 11, 4233.	1.6	3
132	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	2.9	3
133	Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations. <i>Journal of Personalized Medicine</i> , 2021, 11, 917.	1.1	3
134	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10501-10501.	0.8	3
135	The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11601-e11601.	0.8	3
136	Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. <i>Reviews in Obstetrics and Gynecology</i> , 2013, 6, 165-73.	0.7	3
137	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
138	Identification and management of familial breast cancer in Austria. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 32, .	0.3	2
139	Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 233-236.	1.0	2
140	PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1002-1002.	0.8	2
141	A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline <i>BRCA1</i> mutation (BRCA-P Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS10616-TPS10616.	0.8	2
142	Climacteric Complaints after Breast Cancer – Is HRT an Option?. <i>Breast Care</i> , 2008, 3, 9-9.	0.8	1
143	Neoadjuvant Endocrine Therapy in Breast Cancer. <i>Breast Care</i> , 2008, 3, 303-308.	0.8	1
144	Correlation between preoperative radiological and postoperative pathological tumor size in patients with HER2+ breast cancer after neoadjuvant chemotherapy plus trastuzumab and pertuzumab. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	1

#	ARTICLE	IF	CITATIONS
145	Abstract 878: Contraceptive use and ovarian cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: A prospective cohort study. <i>Cancer Research</i> , 2021, 81, 878-878.	0.4	1
146	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptorâ€“Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021, 27, 5931-5938.	3.2	1
147	Residual breast tissue after mastectomy in non high risk and BRCA mutated patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1061-1061.	0.8	1
148	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 551-551.	0.8	1
149	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 63-72.	1.0	1
150	Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. <i>Cancer Research</i> , 2022, 82, P1-21-08-P1-21-08.	0.4	1
151	Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer. <i>Cancer Research</i> , 2022, 82, P5-18-02-P5-18-02.	0.4	1
152	Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 570.	1.1	1
153	Homologous recombination deficiency: New biomarkers in innovative treatments. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 357-358.	0.3	0
154	Extraosseous osteoblastoma: A rare cause of breast mass in a prepubertal girl. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04094.	0.2	0
155	Genetic Testing in Breast Cancer: New Standards of Care. <i>Breast Care</i> , 2021, 16, 193-195.	0.8	0
156	Correlation of breast cancer risk in European BRCA2 mutation carriers with birth cohort.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1537-1537.	0.8	0
157	Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 514-514.	0.8	0
158	Are ulcerated breast cancers biologically more aggressive compared to their non-ulcerated counterparts?. <i>Journal of Clinical Oncology</i> , 2012, 30, 21-21.	0.8	0
159	Elevated CSF-1 serum concentrations to predict lymph node metastasis and overall survival in women with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11032-11032.	0.8	0
160	COX2, p16, and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11519-e11519.	0.8	0
161	Effect of reproductive factors and lifestyle on the onset of breast cancer in female BRCA 1 and 2 mutation carriers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1545-1545.	0.8	0
162	Quality of life in subjects who are at high risk for hereditary breast and/or ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12501-e12501.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial).. Journal of Clinical Oncology, 2015, 33, e11603-e11603.	0.8	0
164	Evaluation of pretherapeutic Ki67 as predictive marker for response to neoadjuvant chemotherapy in patients with primary breast cancer.. Journal of Clinical Oncology, 2016, 34, e12500-e12500.	0.8	0
165	The impact on socio-demographic characteristics of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the outing of Angelina Jolie.. Journal of Clinical Oncology, 2016, 34, e13119-e13119.	0.8	0
166	Circulating tumor cells as an early detection tool for BRCA positive women?. Journal of Clinical Oncology, 2016, 34, e13025-e13025.	0.8	0
167	Estrogen abrogates zoledronic acid induced gene expression signature in endocrine sensitive tumor cell lines in vitro.. Journal of Clinical Oncology, 2018, 36, e12570-e12570.	0.8	0
168	Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry. Cancer Research, 2022, 82, P1-16-03-P1-16-03.	0.4	0
169	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. Cancer Research, 2022, 82, GS1-07-GS1-07.	0.4	0
170	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials. Cancer Research, 2022, 82, P1-02-07-P1-02-07.	0.4	0
171	Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A <i>post-hoc</i> analysis of ABCSG-18. Cancer Research, 2022, 82, P1-15-01-P1-15-01.	0.4	0
172	Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. Cancer Research, 2022, 82, P1-02-06-P1-02-06.	0.4	0
173	Abstract P4-12-10: Cancer worry among healthy <i>BRCA</i> mutation carriers in Austria: A pilot study. Cancer Research, 2022, 82, P4-12-10-P4-12-10.	0.4	0
174	Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases. Breast Journal, 2022, 2022, 1-6.	0.4	0